NCT02316626View on ClinicalTrials.gov

Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support

PHASE4CompletedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

May 31, 2016

Conditions
Infertility
Interventions
DRUG

Subcutaneous progesterone

25 mg daily for 14 days

DRUG

Vaginal progesterone

90 mg daily for 14 days

Trial Locations (1)

88100

Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro

All Listed Sponsors
lead

Roberta Venturella

OTHER

NCT02316626 - Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support | Biotech Hunter | Biotech Hunter